CSL Behring
🇧🇪Belgium
Haemocomplettan® P During Aortic Replacement
Phase 2
Completed
- Conditions
- Aortic Aneurysm
- Interventions
- Biological: Saline solutionBiological: Haemocomplettan® P
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 80
- Registration Number
- NCT00701142
- Locations
- 🇩🇪
Medical School Hannover (MHH), Hannover, Germany
A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)
Completed
- Conditions
- Von Willebrand Disease
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 21
- Registration Number
- NCT00701545
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
Phase 4
Completed
- Conditions
- Alpha 1-proteinase Inhibitor DeficiencyEmphysema
- Interventions
- Biological: Alpha1- proteinase inhibitor [human]
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 140
- Registration Number
- NCT00670007
- Locations
- 🇸🇪
Study Site, Malmo, Sweden
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
Phase 3
Completed
- Conditions
- Autosomal Recessive AgammaglobulinemiaCommon Variable ImmunodeficiencyX-linked Agammaglobulinemia
- Interventions
- Biological: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 51
- Registration Number
- NCT00542997
- Locations
- 🇬🇧
Study site, London, United Kingdom
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
Phase 4
Completed
- Conditions
- Common Variable ImmunodeficiencyAgammaglobulinemia
- Interventions
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 18
- Registration Number
- NCT00520494
- Locations
- 🇪🇸
Contact CSL Behring for facility details, Madrid, Spain
Human Fibrinogen - Pharmacokinetics
Phase 2
Completed
- Conditions
- Fibrinogen Deficiency
- Interventions
- Biological: Human Fibrinogen Concentrate
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 15
- Registration Number
- NCT00496262
- Locations
- 🇮🇹
Contact CSL Behring for facility details, Vicenza, Italy
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
Phase 3
Completed
- Conditions
- Primary Immune Deficiency
- Interventions
- Biological: Human Normal Immunoglobulin for Subcutaneous Administration
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 49
- Registration Number
- NCT00419341
- Locations
- 🇺🇸
Study Site, Dallas, Texas, United States
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Phase 3
Completed
- Conditions
- AgammaglobulinemiaCommon Variable ImmunodeficiencyIgG Deficiency
- Interventions
- Drug: Immunoglobulins Intravenous (Human)
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 55
- Registration Number
- NCT00322556
- Locations
- 🇺🇸
Contact CSL Behring for facility details, Dallas, Texas, United States
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 57
- Registration Number
- NCT00292981
- Locations
- 🇨🇦
Contact CSL Behring for facility details, Ottawa, Ontario, Canada
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
Phase 4
Completed
- Conditions
- EmphysemaAlpha1-proteinase Inhibitor Deficiency
- Interventions
- Biological: Alpha1-proteinase inhibitorOther: Placebo
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 180
- Registration Number
- NCT00261833
- Locations
- 🇸🇪
Study Site, Malmo, Sweden